NDA 205625 · Glaxosmithkline
Arnuity Ellipta
Fluticasone Furoate · Inhalation
Last checked: Nov 20, 2026Latest source record: Oct 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Aug 20, 2014
Approved uses
3
Original approval plus efficacy supplements
Registered trials
737
240 Phase 3, 19 recruiting
FAERS reports
9,896
6,929 serious, 616 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 6, 2025.
Fluticasone Furoate ELLIPTA is indicated for the maintenance treatment of asthma in adult and pediatric patients aged 5 years and older. Limitations of Use Fluticasone Furoate ELLIPTA is NOT indicated for the relief of acute bronchospasm. Fluticasone Furoate ELLIPTA is an inhaled corticosteroid indicated for the maintenance treatment of asthma in adult and pediatric patients aged 5 years and older. ( 1 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1 , 5.2 )
Mechanism: Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is approximately 29.9 times that of dexamethasone and 1.7 times that of fluticasone propionate. The clinical relevance of these findings is unknown. The precise mechanism through which fluticasone furoate affects asthma symptoms is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 1, 2023 Supplement 9 · Efficacy LetterLabel
- May 17, 2018 Supplement 5 · Efficacy LabelLetter
- Aug 20, 2014 Original approval · Type 5 - New Formulation or New Manufacturer ReviewSummary ReviewPediatric Clinical Pharmacology Review
3 products under this application
- ARNUITY ELLIPTA · FLUTICASONE FUROATE 0.2MG/INH · POWDER, INHALATION · Prescription
- ARNUITY ELLIPTA · FLUTICASONE FUROATE 0.05MG/INH · POWDER, INHALATION · Prescription
- ARNUITY ELLIPTA · FLUTICASONE FUROATE 0.1MG/INH · POWDER, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluticasone Furoate" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01313676 · 16,568 participants · Start Jan 25, 2011 · Primary completion Jul 15, 2015
Drug: fluticasone furoate/vilanterol; fluticasone furoate and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 1,611 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01475721 · 11,751 participants · Start Nov 18, 2011 · Primary completion Jun 23, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 4 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 808 sites in all
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02164513 · 10,355 participants · Start Jun 30, 2014 · Primary completion Jul 17, 2017
Drug: fluticasone furoate (FF); vilanterol (VI) and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 998 sites in all
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01462344 · 6,250 participants · Start Nov 17, 2011 · Primary completion Nov 1, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 2 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 530 sites in all
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268216 · 6,228 participants · Start Sep 2000 · Primary completion Nov 2005
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 459 sites in all
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01706198 · 4,233 participants · Start Nov 1, 2012 · Primary completion Dec 1, 2016
Drug: fluticasone furoate + vilanterol; inhaled corticosteroid with or without a long acting beta2-agonist · For: Asthma
Sites: Altrincham, United Kingdom; Bowdon, United Kingdom; Cheadle, United Kingdom · 180 sites in all
- QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01782326 · 3,362 participants · Start Jul 2013 · Primary completion Sep 2015
Drug: QVA149; Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Ciudad de Buenos Aires, Argentina; Buenos Aires, Argentina; Caba, Argentina · 499 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,572
- drug ineffective1,570
- asthma1,315
- off label use926
- cough911
- wheezing908
- therapeutic product effect incomplete766
- nausea686
- pain665
- pneumonia661
- macular degeneration632
- malaise620
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 17 |
| 2011 | 52 |
| 2012 | 266 |
| 2013 | 43 |
| 2014 | 76 |
| 2015 | 156 |
| 2016 | 219 |
| 2017 | 423 |
| 2018 | 583 |
| 2019 | 690 |
| 2020 | 852 |
| 2021 | 1,246 |
| 2022 | 1,096 |
| 2023 | 1,134 |
| 2024 | 1,145 |
| 2025 | 1,105 |
| 2026 | 785 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Arnuity Ellipta (Fluticasone Furoate)
2024 spending
$200M
Beneficiaries
181,821
659,581 claims
Per beneficiary
$1,099
$7.37 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $80,943,847 |
| 2021 | $85,013,031 |
| 2022 | $88,815,140 |
| 2023 | $98,260,735 |
| 2024 | $199,856,123 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Lipson DA, Barnhart F, Brealey N, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.
Sousa-Pinto B, Vieira RJ, Brozek J, et al. · J Allergy Clin Immunol 2024 · Systematic Review, Meta-Analysis
- Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis.
Sousa-Pinto B, Vieira RJ, Bognanni A, et al. · Allergy 2025 · Systematic Review, Network Meta-Analysis
- FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA, Barnacle H, Birk R, et al. · Am J Respir Crit Care Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA, Bailes Z, Barnes N, et al. · Lancet Respir Med 2021 · Clinical Trial, Phase III, Comparative Study
- Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study.
Boulet LP, Abbott C, Brusselle G, et al. · J Allergy Clin Immunol Pract 2024 · Research Support, Non-U.S. Gov't, Randomized Controlled Trial
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.